Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13466841 | 0.90 | BACE1 (0.64) | BACE1BACE2 | |
| SCHEMBL18567803 | 0.90 | BACE1 (0.52) | BACE1 | |
| SCHEMBL13466603 | 0.85 | BACE1 (0.61) | BACE1BACE2 | |
| SCHEMBL10329044 | 0.84 | BACE1 (0.56) | BACE1BACE2 | |
| SCHEMBL18567390 | 0.80 | BACE1 (0.49) | BACE1BACE2 | |
| SCHEMBL15693484 | 0.80 | BACE1 (0.65) | BACE1BACE2 | |
| SCHEMBL13466832 | 0.79 | BACE1 (0.55) | BACE1BACE2 | |
| SCHEMBL15694786 | 0.79 | BACE1 (0.62) | BACE1BACE2 | |
| SCHEMBL13466604 | 0.79 | BACE1 (0.57) | BACE1BACE2 | |
| SCHEMBL13466842 | 0.79 | BACE1 (0.65) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2697210-B1 | 5-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9499502-B2 | 5-substituted iminothiazines and their mono- and dioxides as BACE inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499502-B2 | 5-substituted iminothiazines and their mono- and dioxides as BACE inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20140128382-A1 | 5-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO- AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME LLC | 2014-05-08 | — | — | US | disclosed |
| US-20140128382-A1 | 5-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO- AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME LLC | 2014-05-08 | — | — | US | disclosed |
| WO-2012139425-A1 | 5-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS,COMPOSITIONS,AND THEIR USE | SCHERING CORPORATION (US) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128382-A1 | 5-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO- AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, BACE2, PSEN1 | BACE1 1/4885BACE2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.